3681 — Sinomab Bioscience Share News
0.000.00%
Last trade - 00:00- HK$1.46bn
- HK$1.53bn
Brief: SinoMab Bioscience Posts HY Loss RMB134.1 Million
Brief: Sinomab Bioscience Got IND Approval For SM17 By NMPA
Brief: Sinomab Bioscience Says Investigational NDA For Atopic Dermatitis Accepted By Center For Drug Evaluation Of NMPA
Brief: Sinomab Bioscience Says IND Application For SM17 Has Been Accepted By NMPA Of China
Brief: Sinomab Bioscience Says Phase III Clinical Study Of Sm03 In Rheumatoid Arthritis Meets Primary Endpoint
Brief: SinoMab BioScience Posts FY Loss Of RMB284.2 Million
Brief: Sinomab Bioscience Agreed To Allot & Issue 28.7 Mln Subscription Shares
Brief: Sinomab Bioscience Says For Suciraslimab, Preliminary Result For Phase Iii Study At Week 24 Is Expected In Q3
On 22 Aug Ind For Neuromyelitis Optica Spectrum Disorder For Sn1011 Was Approved By Nmpa
Brief: SinoMab Bioscience Says HY Loss RMB143.8 Mln
Brief: Sinomab Bioscience Says NMPA Nods IND For Drug For Neuromyelitis Optica Spectrum Disorder
Brief: Sinomab Bioscience Says Ind Approval For Sn1011 By China's Nmpa
Brief: Sinomab Bioscience Posts Loss For Year RMB288.2 Mln Vs RMB122.6 Mln
Brief: Sinomab Bioscience Says IND Application For SM17 Was Approved By U.S. FDA
Brief: Sinomab Bioscience Says Investigational New Drug Application For Sm17 Was Accepted
Brief: SinoMab Bioscience Says IND Application For SN1011 Filed With And Accepted By Center For Drug Evaluation Of NMPA
Brief: Sinomab Bioscience Says Sn1011 Obtains Approval For New Indication From NMPA
Brief: SinoMab BioScience Says FY Loss RMB122.6 Mln
Brief: Sinomab Bioscience To Sell Units Of Class A Participating Shares In China Healthcare Fund